Laurion Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Laurion Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$73K	–	1047
2021 Q1	$73K	Buy	+10,000	New	+$86.3K	﹤0.01%	721
2018 Q2	–	Sell	-14,162	Closed	-$411K	–	1707
2018 Q1	$411K	Buy	+14,162	New	+$414K	﹤0.01%	1057

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Laurion Capital Management's AVEO Position: Q2 2021 in Review

Laurion Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 10,000 shares — an estimated $73K sold.

Laurion Capital Management first reported a position in AVEO in Q1 2018 and held it in 2 quarters. The position peaked at $411K in Q1 2018. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

Laurion Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Laurion Capital Management sold 10,000 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $73K.
Laurion Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
Laurion Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $411K in Q1 2018.
63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.